Erratum to: Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease [Dig Dis Sci, DOI 10.1007/s10620-015-3797-3];Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease

Digestive Diseases and Sciences

Volumn 60, Issue 12, 2015, Pages 3620-3630

  Wilson, Aze ^a   Teft, Wendy A ^a   Morse, Bridget L ^a   Choi, Yun Hee ^a   Woolsey, Sarah ^a   DeGorter, Marianne K ^a   Hegele, Robert A ^a   Tirona, Rommel G ^a   Kim, Richard B ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Biomarker; Inflammatory bowel disease; Microbial mammalian co metabolism; Trimethylamine N oxide

Indexed keywords

BIOLOGICAL MARKER; CARNITINE; CHOLINE; FLAVIN MONOOXYGENASE 3; PREDNISONE; QUERCETIN; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE; METHYLAMINE; TRIMETHYLOXAMINE;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIMETHYLAMINE OXIDE BLOOD LEVEL; ULCERATIVE COLITIS; ADOLESCENT; BLOOD; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLAMINES; MIDDLE AGED; YOUNG ADULT;

EID: 84946412864     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3826-2     Document Type: Erratum

References (65)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:9.
2. Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology. 1991;100:350–358.
3. Su C, Lichtenstein GR. Sleisenger and Fordtran’s gastrointestinal and liver diseases: pathophysiology/diagnosis/management, vol. 2. Philadelphia, PA: Saunders Elsevier; 2006.
4. Prideaux L, De Cruz P, Ng SC, et al. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18:1340–1355.
5. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Trans Res J Lab Clin Med. 2012;159:313–325.
6. Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407–1415.
7. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–665.
8. Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl. 2012;1:15–21.
9. Frank DN, St. Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780–13785.
10. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–180.
11. Hayashi H, Sakamoto M, Benno Y. Phylogenetic analysis of the human gut microbiota using 16s rDNA clone libraries and strictly anaerobic culture-based methods. Microbiol Immunol. 2002;46:535–548.
12. Lay C, Rigottier-Gois L, Holmstrom K, et al. Colonic microbiota signatures across five northern european countries. Appl Environ Microbiol. 2005;71:4153–4155.
13. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science (New York, NY). 2005;308:1635–1638.
14. Gill SR, Pop M, DeBoy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science (New York, NY). 2006;312:1355–1359.
15. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science (New York, NY). 2011;334:105–108.
16. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222–227.
17. Rajca S, Grondin V, Louis E, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn’s disease. Inflamm Bowel Dis. 2014;20:978–986.
18. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685–693.
19. Takaishi H, Matsuki T, Nakazawa A, et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol (IJMM). 2008;298:463–472.
20. Schwiertz A, Jacobi M, Frick J-S, et al. Microbiota in pediatric inflammatory bowel disease. J Pediatr. 2010;157:240.e241–244.e241.
21. Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139:1844.e1841–1854.e1841.
22. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576–585.
23. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63.
24. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–1584.
25. Ussher JR, Lopaschuk GD, Arduini A. Gut microbiota metabolism of l-carnitine and cardiovascular risk. Atherosclerosis. 2013;231:456–461.
26. Swann J, Richards S, Shen Q, et al. Culture-independent analysis of the human gut microbiota and their activities. New Jersey: Wiley; 2011.
27. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005;106:357–387.
28. Cashman JR, Akerman BR, Forrest SM, et al. Population-specific polymorphisms of the human FMO3 gene: significance for detoxication. Drug Metab Dispos Biol Fate Chem. 2000;28:169–173.
29. Treacy EP, Akerman BR, Chow LM, et al. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet. 1998;7:839–845.
30. Zeisel SH, Wishnok JS, Blusztajn JK. Formation of methylamines from ingested choline and lecithin. J Pharmacol Exp Therap. 1983;225:320–324.
31. Craciun S, Balskus EP. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci. 2012;109:21307–21312.
32. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2004;1:189–195.
33. Parikh NI, Vasan RS. Assessing the clinical utility of biomarkers in medicine. Biomark Med. 2007;1:419–436.
34. Wang Z, Levison B, Hazen JE, Donahue L, Li X, Hazen SL. Measurement of trimethylamine-n-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. Anal Biochem. 2014;455:35–40.
35. Stein J, Schröder O, Milovic V, et al. Mercaptopropionate inhibits butyrate uptake in isolated apical membrane vesicles of the rat distal colon. Gastroenterology. 1995;108:673–679.
36. Stein J, Zores M, Schröder O. Short-chain fatty acid (SCFA) uptake into caco-2 cells by a pH-dependent and carrier mediated transport mechanism. Eur J Nutr. 2000;39:121–125.
37. Schröder O, Opritz J, Stein J. Substrate and inhibitor specificity of butyrate uptake in apical membrane vesicles of the rat distal colon. Digestion. 2000;62:152–158.
38. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1:514.
39. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29–32.
40. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. Retrieved from http://www.R-project.org.
41. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team. Nlme: linear and nonlinear mixed effects models. R package version 3.1-117. Vienna, Austria: R Foundation for Statistical Computing; 2014. Retrieved from http://CRAN.R-project.org/package=nlme.
42. von Elm E, Altman DG, Egger M, et al. Strobe initiative. The strengthening the reporting of observational studies in epidemiology (strobe)statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349.
43. Patel N, Alkhouri N, Eng K, et al. Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther. 2014;40:498–507.
44. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489–1499.
45. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.
46. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13:R79.
47. Guarner F, Malagelada J-R. Gut flora in health and disease. Lancet. 2003;361:512–519.
48. Zheng X, Xie G, Zhao A, et al. The footprints of gut microbial–mammalian co-metabolism. J Proteome Res. 2011;10:5512–5522.
49. Sepehri S, Kotlowski R, Bernstein CN, et al. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:675–683.
50. Kang S, Denman SE, Morrison M, et al. Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis. 2010;16:2034–2042.
51. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55:205–211.
52. Dawiskiba T, Deja S, Mulak A, et al. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. World J Gastroenterol (WJG). 2014;20:163–174.
53. Dhurandhar NV, Schoeller D, Brown AW, et al. Energy balance measurement: when something is not better than nothing. Int J Obes (Lond). 2014. doi:10.1038/ijo.2014.199.
54. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–563.
55. Bennett BJ, de Aguiar Vallim TQ, Wang Z, et al. Trimethylamine-n-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17:49–60.
56. Miller CA, Corbin KD, da Costa KA, et al. Effect of egg ingestion on trimethylamine-n-oxide production in humans: a randomized, controlled, dose-response study. Am J Clin Nutr. 2014;100:778–786.
57. Chen Y, Patel NA, Crombie A, et al. Bacterial flavin-containing monooxygenase is trimethylamine monooxygenase. Proc Natl Acad Sci USA. 2011;108:17791–17796.
58. Berrill JW, Green JT, Hood K, et al. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013;38:44–51.
59. Burgmann T, Clara I, Graff L, et al. The manitoba inflammatory bowel disease cohort study: prolonged symptoms before diagnosis—how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4:614–620.
60. Zschocke J, Kohlmueller D, Quak E, et al. Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet. 1999;354:834–835.
61. Raimondi F, Santoro P, Barone MV, et al. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol. 2008;294:G906–G913.
62. Cipriani S, Mencarelli A, Chini MG, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE [Electronic Resource]. 2011;6:e25637.
63. Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60:10.
64. Attinkara R, Mwinyi J, Truninger K, et al. Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Res Notes. 2012;5:12.
65. Nijmeijer RM, Gadaleta RM, van Mil SW, et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS ONE [Electronic Resource]. 2011;6:e23745.